In a rodent model of schizophrenia susceptibility, adolescent exposure to synthetic cannabinoids increased the proportion of genetically at-risk rats that developed a schizophrenia-like dopamine phenotype, while leaving non-susceptible rats unaffected.
Read this if you want to understand the science behind why some teenagers develop psychosis after using cannabis while most do not.
Only genetically susceptible rats (about 40%) were affected by adolescent cannabinoid exposure
What the researchers found
Researchers used a novel rodent model where about 40% of rats carry genetic susceptibility to a schizophrenia-like phenotype. When these susceptible rats were exposed to a synthetic cannabinoid (WIN55,212-2) during adolescence, a significantly larger proportion developed the characteristic hyperdopaminergic state associated with schizophrenia after reaching adulthood.
Critically, the same adolescent synthetic cannabinoid exposure had no observable effect on the non-susceptible rats. This mirrors the human epidemiological pattern where most adolescents who use cannabis do not develop psychosis, but those with genetic vulnerability are at elevated risk.
The acquired schizophrenia-like phenotype appeared to involve alterations in parvalbumin interneuron function within the hippocampus. Additionally, adolescent exposure to an endocannabinoid upregulator (URB597) also increased the proportion of susceptible rats developing elevated dopamine neuron activity, but without changing behavioral sensitivity to amphetamine, highlighting important differences between exogenous and endogenous cannabinoid signaling.
Why it matters
This study provides experimental evidence for the gene-environment interaction model of cannabis and psychosis. The finding that only genetically susceptible animals were affected by adolescent cannabinoid exposure explains why the vast majority of young cannabis users do not develop psychosis while a vulnerable minority does. It also identifies specific neural mechanisms that may mediate this risk.
The numbers in context
Approximately 40% of F2 MAM rats naturally display schizophrenia-like phenotype. Synthetic cannabinoid dose: 0.2 mg/kg WIN55,212-2. Endocannabinoid upregulator dose: 0.3 mg/kg URB597. Adolescent synthetic cannabinoid exposure significantly increased proportion of susceptible rats developing hyperdopaminergic phenotype. Non-susceptible rats showed no changes.
How the study worked
The F2 methylazoxymethanol acetate rat model was used, where approximately 40% of offspring display schizophrenia-like features. Adolescent rats received either WIN55,212-2 (synthetic cannabinoid, 0.2 mg/kg), URB597 (endocannabinoid upregulator, 0.3 mg/kg), or vehicle. Adult outcomes included dopamine neuron activity recordings and behavioral amphetamine sensitivity testing.
What this study cannot tell us
Animal models cannot fully replicate human schizophrenia. The synthetic cannabinoid WIN55,212-2 is more potent and less nuanced than natural cannabis. The dosing regimen may not reflect typical human use patterns. Parvalbumin interneuron changes were suggested but not fully characterized. The model captures some but not all features of schizophrenia.
How to read the evidence
This is a well-designed animal study using a validated model of schizophrenia susceptibility, providing moderate evidence for the mechanism of gene-environment interaction.
When this study was published
Published in 2018. The F2 MAM rat model continues to be used in schizophrenia and cannabinoid research.
The bigger picture
This work bridges the gap between human epidemiological observations and biological mechanisms. While human studies have long shown that cannabis increases psychosis risk more in genetically vulnerable individuals, this animal model demonstrates a plausible mechanism involving dopamine neuron activity and parvalbumin interneuron function in the hippocampus.
Questions still open
- Could parvalbumin interneuron function serve as a biomarker for vulnerability to cannabis-induced psychosis? Would earlier or later exposure windows produce different results? How do natural cannabis compounds compare to synthetic cannabinoids in this model?
Common questions
Why don't all cannabis users develop psychosis?
Are synthetic cannabinoids more dangerous than natural cannabis for psychosis risk?
Read the original research
Adolescent Synthetic Cannabinoid Exposure Produces Enduring Changes in Dopamine Neuron Activity in a Rodent Model of Schizophrenia Susceptibility.
The international journal of neuropsychopharmacology, 21(4), 393-403
Citation
Aguilar, David D; Giuffrida, Andrea; Lodge, Daniel J. (2018). Adolescent Synthetic Cannabinoid Exposure Produces Enduring Changes in Dopamine Neuron Activity in a Rodent Model of Schizophrenia Susceptibility.. The international journal of neuropsychopharmacology, 21(4), 393-403. https://doi.org/10.1093/ijnp/pyy003
Explore the wider topic
- THC Purity and Potency: What the Label Actually Means
- Dab and Concentrate Withdrawal: Why It Hits Harder
- Delta-8 THC: Addiction, Withdrawal, and What We Don't Know
- Edible Addiction and Withdrawal: What Makes It Different
- Edibles and Psychosis: When a Bad Trip Becomes an Emergency
- Vaping vs Smoking vs Edibles: A Harm Reduction Guide
- How Cannabis Products Are Made: From Plant to Concentrate to Edible
- Laced Weed and Contaminated Vapes: Real Risks vs Myths
- Legal vs Street Weed: Quality, Safety, and What You're Actually Smoking
- Quitting Weed Pens and Dabs: Why Concentrates Hit Different
- Quitting Edibles: Is Withdrawal Different from Smoking?
- Sativa vs Indica: The Myth and the Science Behind Cannabis Strain Labels
- Why Is Weed Withdrawal Worse Now Than 20 Years Ago?